Protocol for the donation of samples by volunteers for laboratory research
ISRCTN | ISRCTN13109642 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN13109642 |
IRAS number | 149078 |
Secondary identifying numbers | DS-10-01, IRAS 149078, 46616 |
- Submission date
- 02/02/2023
- Registration date
- 03/02/2023
- Last edited
- 18/04/2024
- Recruitment status
- Recruiting
- Overall study status
- Ongoing
- Condition category
- Other
Plain English summary of protocol
Background and study aims
This study aims to obtain blood and/or urine, stool, skin, sputum, saliva, mucosal or nasal samples from healthy volunteers and patient volunteers for laboratory research, relating to the causes and treatment of disease, in order to identify markers of disease and drug effect or development of new laboratory methods.
Who can participate?
Men and women 18 years old or over
What does the study involve?
This study will involve ad hoc visits to the Medicines Evaluation Unit. After written informed consent is obtained, participants will be assessed for their eligibility to donate the samples required according to the specific procedure to be undertaken. Participants have one or more of the following samples taken at a single visit: sputum, blood, urine, nasal, stool or skin.
What are the possible benefits and risks of participating?
All sampling procedures are considered safe. There is a small risk of side effects such as bruising, bleeding and infection. This is laboratory research so there is no direct benefit to the participant.
Where is the study run from?
Medicines Evaluation Unit (UK)
When is the study starting and how long is it expected to run for?
November 2009 to December 2030
Who is funding the study?
Investigator initiated and funded
Who is the main contact?
Clinical Research Leader
Contact information
Public
MEU
The Langley Building
Southmoor Road
Manchester
M23 9QZ
United Kingdom
Phone | +44 (0)1619464065 |
---|---|
njackson@meu.org.uk |
Scientific
MEU
The Langley Building
Southmoor Road
Manchester
M23 9QZ
United Kingdom
Phone | +44 (0)1619464065 |
---|---|
njackson@meu.org.uk |
Principal Investigator
MEU
The Langley Building
Southmoor Road
Manchester
M23 9QZ
United Kingdom
Phone | +44 (0)1619464073 |
---|---|
dsingh@meu.org.uk |
Study information
Study design | Observational cross sectional study |
---|---|
Primary study design | Observational |
Secondary study design | Cross sectional study |
Study setting(s) | Pharmaceutical testing facility |
Study type | Diagnostic |
Participant information sheet | Not available in web format, please use the contact details to request a participant information sheet |
Scientific title | Protocol for the donation of blood, urine, stool, dermatological, sputum and nasal samples by healthy volunteers and patient volunteers for laboratory research |
Study objectives | Identifying markers of disease and developing new assays |
Ethics approval(s) | Approved 12/04/2010, North West Preston Research Ethics Committee (HRA Centre Manchester, Barlow House, 3rd Floor, 4 Minshull Street, Manchester M1 3DZ, UK; +44 (0)2071048290; preston.rec@hra.nhs.uk), ref: 10/H1016/25 |
Health condition(s) or problem(s) studied | Healthy volunteers and patient volunteers of all conditions |
Intervention | Participants have one or more of the following samples taken at a single visit: sputum, blood, urine, nasal, stool or skin. |
Intervention type | Other |
Primary outcome measure | Sputum eosinophil counts in stable state measured using cytology at a single timepoint |
Secondary outcome measures | Sputum supernatant cytokines including IL-8 and TNF-α in stable state measured using immunoassay at a single timepoint |
Overall study start date | 01/11/2009 |
Completion date | 31/12/2030 |
Eligibility
Participant type(s) | Mixed |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | At least 2000 |
Key inclusion criteria | 1. Able to give written informed consent 2. Males and females aged over 18 years 3. Procedure specific criteria |
Key exclusion criteria | 1. History of anaemia or identified by haemocue test at screening or other clinically significant haematological disorders for blood donation 2. Current acute illness 3. Pregnancy or breastfeeding 4. History of Hepatitis B/C or HIV infection or a positive test at screen if required by the specific project 5. Volunteers who have donated to the blood transfusion service in the past 4 months, if applicable (applicable for blood donation or if specified for other procedures as per project-specific exclusion criteria) 6. Suspected use of drugs of abuse or positive drug screen, if required 7. Any contraindications for nasal sampling e.g. history of epistaxis, nasal defects, as assessed by the physician 8. Procedure-specific criteria and contraindications for performing the specific procedure 9. Any reason that the physician deems the subject not suitable to undertake the procedure(s) |
Date of first enrolment | 07/05/2010 |
Date of final enrolment | 31/12/2029 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Southmoor Road
Wythenshawe
Manchester
M23 9QZ
United Kingdom
Sponsor information
Research organisation
The Langley Building
Southmoor Road
Manchester
M23 9QZ
England
United Kingdom
Phone | +44 (0)161 9464050 |
---|---|
drogers@meu.org.uk | |
Website | http://www.meu.org.uk/ |
https://ror.org/05e497m36 |
Funders
Funder type
Other
No information available
Results and Publications
Intention to publish date | 01/01/2025 |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not expected to be made available |
Publication and dissemination plan | Planned publications in high-impact peer-reviewed journals, the first one in 2025. |
IPD sharing plan | The datasets generated during and/or analysed during the current study are not expected to be made available due to the exploratory nature of the research and assays. |
Editorial Notes
18/04/2024: A study contact confirmed the record required no changes at this time.
02/03/2023: IRAS number added.
03/02/2023: Trial's existence confirmed by the North West Preston Research Ethics Committee.